Surgical simulation steps into a new phase in ophthalmology

Tern plc

In the niche but technically demanding world of ophthalmology, a new approach to training is gaining ground. The traditional reliance on live surgical observation and supervised repetition is being supplemented, and in some cases, pre-empted, by immersive extended reality. At the centre of this evolution is a structured rollout model that reframes simulation as a progressive system of implementation.

Fundamental XR has laid out a clear, phased framework for XR adoption, beginning with pilot testing and moving deliberately through infrastructure deployment, staff onboarding, content calibration, and outcome tracking. This matters because while extended reality has been circulating in healthcare discussions for years, what has often been missing is a replicable model for institutional uptake, something that works beyond a showcase or demo setting.

What makes this opportunity distinctive is that it bypasses much of the hype surrounding general-use XR platforms. Instead, it targets a clear pain point, surgical training bottlenecks, with a solution that is already seeing traction across professional institutions.

Developing and maintaining specialty-specific content, adapting to new surgical techniques and staying aligned with evolving training standards all require sustained investment. But these same factors create defensible barriers to entry. In fields like ophthalmology, where each device or procedure has unique requirements, the demand for high-fidelity simulation remains acute, and unlikely to be met by generalist solutions.

More importantly, this model may not stay confined to one field. If the implementation roadmap proves successful in ophthalmology, there is a clear logic to extending it into other surgical specialities.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines is building the AI layer beneath pharma marketing

Talking Medicines is shifting pharma marketing from content creation to data control, building the layer AI tools rely on to deliver credible, measurable clinical messaging.

A shift in how IoT is secured by default

KeyScaler 2025 transforms IoT security by automating trust across every device’s lifecycle, from onboarding to decommissioning, turning scalable connectivity and compliance into a built-in feature.

Turning employee sentiment into hard operational data

Workforce wellbeing is becoming a source of operational data, and the companies acting early are already reducing risk.

Tern Plc Extends Convertible Loan Maturities in Talking Medicines to Strengthen Exit Strategy

Tern Plc extends all convertible loan maturities in Talking Medicines to 2029, enhancing its strategic position for future exit.

A new frontier for medical device trust and patient safety

Connected medical device risk is rising and a platform that automates identity, credential and data‑protection lifecycles may become an infrastructure segment worth watching.

When HCP Dialogue Becomes Quantifiable Intelligence

Talking Medicines’ DrugVoice platform turns real‑world HCP dialogue into measurable insight, letting brand‑teams forecast message resonance before launch.

Search

Search